By Mary Stuart
It’s time for the annual road shows, and the management of Stryker Corp. has been speaking at the meetings of...
In January, Stryker made an equity investment in neurostimulation start-up Afferent, operating in stroke rehabilitation. The deal is part of Stryker's growth plans to invest in emerging markets that are adjacent to core business segments. For Afferent, the partnership is validation of its unique platform, which stimulates afferent (incoming) rather than efferent (outgoing) nerve centers.
By Mary Stuart
It’s time for the annual road shows, and the management of Stryker Corp. has been speaking at the meetings of...
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.